Jefferies names five top tech picks after August reporting season

GlobalFoundries (GFS) and Taiwan Semiconductor (TSM) will jointly produce silicon interposers in the U.S. GFS shares rose 4% in premarket trading. The deal involves expanding GFS's Malta, N.Y. facility.

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia

Bristol Myers Squibb reported positive results from a Phase 3 trial for Zenbexus, a treatment for multiple myeloma. The drug is already FDA-approved for another blood cancer. The trial success could expand Zenbexus's market potential.

Elon Musk clarified that his companies will build and operate Terafab, an AI chip complex in Texas, with TSMC (TSM) potentially subleasing part of it. This decision impacts Tesla (TSLA), SpaceX, and Intel, as it reduces speculation about TSMC taking over the project. Musk's statement follows discussions with TSMC about possible cooperation, which had sparked uncertainty about Intel's role.

Edgewise Therapeutics (EWTX) dosed the first patient in its Phase 2 EQUINOX-HFpEF trial for heart failure treatment EDG-15400. The study will evaluate safety and efficacy in 90 adults with HFpEF, with results expected in 2026. The drug aims to improve cardiac relaxation, a key issue in HFpEF.

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.